<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827578</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TASO-301</org_study_id>
    <nct_id>NCT02827578</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia</brief_title>
  <official_title>Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia : a Randomized, Double Blinded, Parallel Design, Active Controlled, Multi-center, Phase 3 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Tamsulosin/Solifenacin Combination therapy in Patients with voiding
      symptoms and moderate to severe storage symptoms due to Benign Prostate Hyperplasia : a
      randomized, double blinded, parallel design, active controlled, multi-center, phase 3
      clinical trial
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of TUFS((Total Urgency and Frequency Score)/24h</measure>
    <time_frame>From baseline at week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of total IPSS(International prostate symptom score)</measure>
    <time_frame>From baseline at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of urgency/24h</measure>
    <time_frame>From baseline at week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of voiding frequency/24h</measure>
    <time_frame>From baseline at week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of nocturnal frequency/24h</measure>
    <time_frame>From baseline at week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of urge urinary incontinence frequency/24h</measure>
    <time_frame>From baseline at week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IPSS(International prostate symptom score)-sub score</measure>
    <time_frame>From baseline at week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of PPBC(Patient perception of bladder condition)</measure>
    <time_frame>From baseline at week 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of IPSS(International prostate symptom score) QoL(Quality of Life)</measure>
    <time_frame>From baseline at week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGIC(Patient Global Impression of change) and CGIC(Clinician Global Impression of change)</measure>
    <time_frame>From baseline at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of subjects who are decreased total IPPS(International prostate symptom score) more than 4</measure>
    <time_frame>From baseline at week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin + Solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin and Solifenacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin + Solifenacin Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin and Solifenacin placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Tamsulosin</description>
    <arm_group_label>Tamsulosin + Solifenacin</arm_group_label>
    <arm_group_label>Tamsulosin + Solifenacin Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Solifenacin</description>
    <arm_group_label>Tamsulosin + Solifenacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin placebo</intervention_name>
    <description>Solifenacin placebo</description>
    <arm_group_label>Tamsulosin + Solifenacin Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male aged 45 years old or older

          2. Subjects with benign prostatic hyperplasia diagnosed by digital rectal examination

          3. Subjects with lower urinary tract symptom suggestive of benign prostate hyperplasia,
             who spontaneously agree to join and sign to the consent form

        Exclusion Criteria:

          1. Subjects who have a history of the lower urinary tract cancer, including prostate
             cancer and bladder cancer within the past 5 years

          2. Subjects who have acute urinary retention within 4 weeks before screening

          3. Subjects who have clinically significant severe cardiovascular disease(unstable
             angina, myocardial infarction or arrhythmia) within 6 months before screening

          4. Subjects who have hypersensitivity to investigational product or sulfa medications

          5. Subjects who were suspected or confirmed calculus of lower urinary tract, calculus of
             bladder (except for complete recovery,)

          6. Subjects who have myasthenia gravis, narrow angle glaucoma or autonomic neuropathy

          7. Subjects who have cataract or glaucoma scheduled to be operated in the study duration.

          8. Subjects who have hereditary problems of galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          9. Subjects who are judged by the investigators to be unsuitable to participate in the
             clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>moah Son</last_name>
    <email>sonmoah@ildong.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kyu Sung Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

